Sponsor: Agilent GenohmThis GEN webinar, sponsored by Agilent Genohm, will focus on two key areas: how implementing a sample and workflow management system such as SLIMS can have a major impact on a biobank’s efficiency, and how integrating these sample management systems with other technologies used by biobanks, such as freezers and readers for tracking samples, can create even greater value in the solutions biobanks have to offer.
Sponsored by: 10x Genomics In this sponsored GEN webinar, we will hear how Chromium Connect from 10x Genomics was designed to simplify single-cell library prep workflows and increase laboratory productivity. Additionally, the 10x-pert presenters will demonstrate how the new automated system will enable walkaway convenience while generating consistent single-cell gene expression results.
Sponsor: LonzaIn this GEN webinar, sponsored by Lonza, we will hear about a high-throughput platform for CRISPR-Cas9 gene editing in primary human cells for the robust functional interrogation of complex biological processes and disease states. We also learn about the clinically relevant scale of gene-editing, platforms, and approaches, process development considerations for bringing these gene-edited therapies to the clinic.
Sponsor: CarterraIn this Carterra sponsored webinar, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
Sponsor: 10x GenomicsSingle B cell screening methods have emerged as efficient antibody discovery technologies. In this GEN webinar sponsored by 10x Genomics, we’ll hear about the application of LIBRA-Seq to screen B cells from human HIV-infection samples against large libraries of viral antigens for antibody discovery, as well as about the identification of a new broadly neutralizing HIV-1 antibody.
Please wait while you are redirected to the right page...